Royal Bank of Canada’s AstraZeneca AZN Stock Holding History

Royal Bank of Canada’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-50	Closed	-$4K	–	6690
2019 Q2	$4K	Sell	50 -50	-50%	-$3.92K	﹤0.01%	6374
2019 Q1	$8K	Buy	+100	New	+$7.88K	﹤0.01%	6074

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Royal Bank of Canada's AZN Position: Q2 2026 in Review

Royal Bank of Canada increased its AstraZeneca (AZN) stake by 0.4% in Q2 2026, buying an estimated $7.72M and bringing the position to 10,427,503 shares worth $1.98B. The position accounts for 0.29% of the portfolio, ranked #64.

Royal Bank of Canada first reported a position in AZN in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.05B in Q1 2026. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Royal Bank of Canada held 10,427,503 shares of AstraZeneca worth $1.98B as of Q2 2026.
Royal Bank of Canada bought 41,048 AstraZeneca shares in Q2 2026, an estimated $7.72M.
AstraZeneca made up 0.29% of Royal Bank of Canada's portfolio in Q2 2026, its #64 holding.
Royal Bank of Canada first reported a position in AstraZeneca in Q2 2013 and has held it in 53 quarters since.
Royal Bank of Canada's AstraZeneca position peaked at $2.05B in Q1 2026.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.